Olprinone hydrochloride hydrate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: Olprinone hydrochloride hydrate
• 英文别名: 5-imidazo[1,2-a]pyridin-6-yl-6-methyl-2-oxo-1H-pyridine-3-carbonitrile;hydrate;hydrochloride
• 化学式: C14H13ClN4O2
• 分子量: 304.73
• InChiKey: BFZDXWYVGHGCMK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.47
• 重原子数：
  21
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  71.2
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• MEDICINAL COMPOSITION FOR TREATING INTRACTABLE HEART DISEASE
  申请人：Osaka University

  公开号：EP3569249A1

  公开（公告）日：2019-11-20

  The present invention provides a pharmaceutical composition for use in treating an intractable heart tissue fibrosis disease accompanied by chronic heart failure. The pharmaceutical composition for use in treating an intractable heart tissue fibrosis disease accompanied by chronic heart failure comprises, as an active ingredient, at least one member selected from the group consisting of protease inhibitors, thromboxane A2 synthase inhibitors, thromboxane A2 synthase antagonists, phosphodiesterase (PDE) inhibitors, tyrosine kinase inhibitors, HMG-CoA reductase inhibitors, and antifibrotic agents. (The pharmaceutical composition includes biodegradable polymer-encapsulated, long-acting preparations thereof.)

  本发明提供了一种用于治疗伴有慢性心力衰竭的难治性心脏组织纤维化疾病的药物组合物。用于治疗伴有慢性心力衰竭的难治性心脏组织纤维化疾病的药物组合物包括至少一种选自由蛋白酶抑制剂、血栓素 A2 合酶抑制剂、血栓素 A2 合酶拮抗剂、磷酸二酯酶 (PDE) 抑制剂、酪氨酸激酶抑制剂、HMG-CoA 还原酶抑制剂和抗纤维化剂组成的组的成员作为活性成分。(药物组合物包括其中的生物可降解聚合物包封长效制剂）。
• COMBINATION THERAPIES
  申请人：Pharmacia & Upjohn Company LLC

  公开号：EP1620083A2

  公开（公告）日：2006-02-01
• EP3838246A1
  申请人：——

  公开号：EP3838246A1

  公开（公告）日：2021-06-23
• Medicinal Composition for Treating Intractable Heart Disease
  申请人：Osaka University

  公开号：US20190343841A1

  公开（公告）日：2019-11-14

  The present invention provides a pharmaceutical composition for use in treating an intractable heart tissue fibrosis disease accompanied by chronic heart failure. The pharmaceutical composition for use in treating an intractable heart tissue fibrosis disease accompanied by chronic heart failure comprises, as an active ingredient, at least one member selected from the group consisting of protease inhibitors, thromboxane A 2 synthase inhibitors, thromboxane A 2 synthase antagonists, phosphodiesterase (PDE) inhibitors, tyrosine kinase inhibitors, HMG-CoA reductase inhibitors, and antifibrotic agents. (The pharmaceutical composition includes biodegradable polymer-encapsulated, long-acting preparations thereof.)
• DRUG MANAGEMENT METHOD FOR KIT FORMULATION REQUIRING DOSE ADJUSTMENT
  申请人：REGIMEN KIT, INC.

  公开号：US20210205172A1

  公开（公告）日：2021-07-08

  A packaging container for a drug having a recording medium and/or an identification mark for recording and updating one or more arbitrary information(s) selected from the group consisting of the information: an active ingredient of a drug, usage of a drug, drug dose, date of manufacture of a drug, expiration date of a drug, drug shipping date of a drug, traceability of drug delivery route from manufacturing to usage of a drug, and storage conditions (e.g., temperature, light (dark/light), humidity, etc.) including storage temperature and changes thereof, information including the administration date of a drug and a breakdown of the administration, amount of drug presented in drug-enclosing portion.